Hall Kimball 4

What Happened
Hall Kimball, a director of Vera Therapeutics (VERA), was granted a derivative award covering 17,084 shares on 2026-05-21. The grant is reported at $0.00 (no cash paid at grant) and is described in the filing as shares subject to an option that will vest under the schedule below.

Key Details

• Transaction date: 2026-05-21; Form 4 filed: 2026-05-26 (filing appears within the required reporting window).
• Security/amount: derivative award (option) for 17,084 shares; reported acquisition price $0.00.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Vesting (Footnote F1): the option vests in full on the earlier of the first anniversary of the grant date or the Company’s 2027 annual meeting, subject to the reporting person’s continuous service; the award also vests in full upon a change in control (subject to continuous service).
• Transaction type: Award/Grant (code A) — not an open-market purchase or sale.

Context
This is a compensatory derivative grant to a director (routine for board compensation) rather than a market purchase or sale. Because the instrument is an option-like award with vesting conditions, it does not represent immediately tradable shares unless and until vested (and, if applicable, exercised).